Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline.

Gary T FergusonAsif ShaikhKay TetzlaffAchim MuellerHelgo MagnussenHenrik Watz

Published in: International journal of chronic obstructive pulmonary disease (2020)

Consistent with results from the overall WISDOM trial population, ICS withdrawal did not increase exacerbation risk in patients taking triple therapy at screening. Patients with a history of frequent exacerbations and higher blood eosinophil counts could benefit from continuation of ICS-based therapy.

Keyphrases

chronic obstructive pulmonary disease
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
cystic fibrosis
prognostic factors
peritoneal dialysis
randomized controlled trial
study protocol
mesenchymal stem cells
air pollution
cell therapy
mechanical ventilation